
For every 2 paid attendees, get the 3rd FREE!

THE smartest business intelligence + 1:1 partnering = the best return on your conference investment.

TA Partnerships delivers companies offering the high-value assets that your future sales demand – plus, you’ll also meet the companies who are looking for exactly the assets you have to offer. The most active in-licensors and out-licensors will all be on hand to create future growth through investments in partnership deals.

If you attend one meeting this year, don’t waste your time picking through hundreds of irrelevant partners. Choose TA Partnerships 2011, whose pharmaceutical, biotechnology and investor attendees are the most senior-level in the business. Space is limited, so register today!

Featured Keynote Session and Case Study

When Bad Things Happen to Good Companies: Responding and Repositioning for Success

In the year Perkins was elected CEO, a late-stage clinical trial of Infinity’s most advanced program failed, and share price dropped 30%. Two other programs in the portfolio faced make or break questions and the future of an important strategic partnership hung in the balance. Key additional capabilities were critical to bringing the company to the next stage of its evolution. The company needed to reprioritize programs, expand and diversify the portfolio, reaffirm an existing partnership and form a new one, as well as building out later stage capabilities. Infinity's leader offers lessons for biopharmaceutical companies large and small.

Adelene Q. Perkins
President and Chief Executive Officer
Infinity Pharmaceuticals, Inc.

Keynote Address

Novel Technologies & Cohorts for Personalized Diagnostics & Therapies

George Church, PhD
Professor of Genetics
Harvard Medical School
Director of the Center for Computational Genetics
Founder/Advisor to 22 companies

Featuring lessons learned from the following speakers:

Gary Gabrielsen
VP, Business Development
Astellas US LLC

Uwe Schoenbeck, PhD

Chief Scientific Officer, External R&D Innovation Worldwide Research and Development

Pfizer

Joseph McCracken

Global Head Business Development & Licensing

Roche Pharma Partnering

Larry Deckelbaum

Vice President, Cardiovascular Medicine

Johnson & Johnson

Elizabeth L. Bachert, PhD

Sr. Director, Worldwide Business Development

Pfizer Inc.

John Delyani

Head Therapeutics, Strategic Alliances

Novartis Institutes for BioMedical Research

Carole A. Wilmot, PhD
Sr. Director, US Business Development
Sanofi

Alexander Schuth
Head of Neuroscience Partnering
Genentech, Inc.

Alethia de León
Global Business Development & Licensing
Head of Search & Evaluation Neuroscience and Ophthalmics
Novartis Pharma AG

John L. Cantello, PhD
Vice President, Business Development
Metabolic Pathways & Cardiovascular Therapy Area Unit
GlaxoSmithKline

Jeffrey Wasserstein
Senior Vice President, Business Development and Strategy
Nycomed US

Fernando Sallés, PhD, CLP
Senior Director, Franchise Licensing Integrator Drug Delivery, Neuroscience and Ophthalmology
External Scientific Affairs, Worldwide Licensing
Merck & Co., Inc.

Daniel J. Curran, MD

Vice President, Corporate Development

Millennium: The Takeda Oncology Company

Ann Barry

Executive Director, Worldwide Business Development

Pfizer Inc.

Neil S. Ryder PhD

Executive Director, Infectious Diseases

Novartis Institutes for BioMedical Research, Inc.

Monica K. Cheng, PhD
Associate Director Global Licensing - Commercial Opportunities & CardioMetabolic Diseases Business Development & Licensing
Boehringer Ingelheim Pharmaceuticals, Inc. Inc.

James Geraghty
Senior Vice President
Genzyme

John Gustofson
Business Development Director
Strategic Partnering and Business Development
Oncology and Infection
AstraZeneca

Milton H. Grannatt, PhD
Vice President & Head, Negotiations, Respiratory & New Growth Opportunities
Global Business Development & Licensing
Novartis

Michael C. Diem, MD
Director, Business Development, Rare Diseases
GlaxoSmithKline

Roger J. Pomerantz, MD, F.A.C.P.
Global Franchise Head for Infectious Diseases and Senior Vice President
Merck & Co., Inc.

John McDonald
Vice President, Business Development
Biogen Idec

Campbell Murray, MD
Managing Director
Novartis Venture Funds

What do you get for your conference investment?

1:1 pre-scheduled meetings with your partners of choice
65+ strategic presentations on how to build your R & D pipeline-both internally and externally
25+ strategies from all the major pharma heads of BD, CEOs and investors
Several practical pre-conference workshops
11+ networking opportunities with the most senior level executives in the biopharma business
60 handpicked TOP projects in the Hottest Therapeutic Areas-Oncology, Metabolic/Cardiovascular, Neuroscience, Inflammatory/Autoimmune Diseases, Infectious Diseases (past nominees include Millennium, Myogen, Isis, Sirtris, BiPar and Kosan-all companies who went on to do big deals!)
View the complete history of alliances, financings and M&As, articles, pipeline data, of all participating companies. Companies in partnering software are all linked to Windhover’s Strategic Transactions, IN VIVO articles and Inteleos clinical pipeline links.

Past Windhover Top 10 Candidates Signed a Total Potential value of $17 BILLION US in acquisitions and alliances. Are you missing out on potential opportunities? Don’t fall behind the curve.

Past Top 10 Nominated Companies - Just a few samples of deal history:

BiPar Sciences Inc. - Sanofi to acquire BiPar Sciences
Sirtris Pharmaceuticals Inc. - GSK acquires sirtuin-targeting firm Sirtris for $720mm
VIA Pharmaceuticals Inc. - VIA expands pipeline with Roche's cardio, metabolic programs
Transition Therapeutics - Eli Lilly, Transition Therapeutics enter diabetes partnership
Sangamo BioSciences - Pfizer gets license to Sangamo's ZFN technology
Portola Pharmaceuticals - Novartis gets global license to Portola's elinogrel
NeurogesX - NeurogesX licenses neuropathic pain treatments to Astellas
Metabasis Therapeutics Inc. - Metabasis uses HepDirect in HCV deal with Roche
Kosan Biosciences Inc. - BMS adds to cancer pipeline in $235mm Kosan takeover
Isis Pharmaceuticals Inc. - Genzyme and Isis enter $1.2bn CV collaboration
ImmunoGen - ImmunoGen grants TAP rights to Bayer for cancer target
DeveloGen - Boehringer to further develop DeveloGen's metabolic program
Combinatorx - Novartis signs cancer deal with CombinatoRx
Bayhill Therapeutics - Genentech gets exclusive rights to Bayhill's BHT3021
Arqule Inc. - ArQule gets $75mm up front in two new deals with Daiichi
Archemix - Archemix to license anti-inflammatory aptamers to GSK
Antisoma - Sanofi buys US rights to Oforta from Antisoma
Acorda Therapeutics - Acorda licenses Biogen Idec ex-US rights to Fampridine-SR

Click Title for More Info

Why Use Windhover Conferences Partnering Software?
• Identify attendees to choose potential partners. • Search database of partnering/investing opportunities(including deal history and related articles). • Communicate and pre-schedule as many meetings as you wish with fellow attendees. • Showcase your company's innovative technology and investment/partnering interests.

2011 Important Partnering Deadlines
Last Chance for Early Bird-Rate 1	9/9/2011
Last Chance for Early Bird-Rate 2	10/31/2011
Partnering Opens (start scheduling meetings)	11/3/2011
Fill Out Your Attendee/Company Profile	11/4/2011
Last Chance for Discounted Rooms (rooms may sell out before this date)	11/8/2011

Each company profile on the TA Partnerships partnering software is linked with Windhover’s Strategic Transactions and IN VIVO articles database to help delegates conduct research on companies they might wish to meet at the conference.

The most comprehensive deals data in the industry, all completely exportable and customizable, Strategic Transactions includes alliances, financings and M&As across biopharmaceuticals, devices, diagnostics and university transfers. Better yet, it’s the only database with available analysis from Windhover’s award-winning editorial staff.

PLUS! View clinical development details, successes, and failures of the products up for partnering!

Each product available for partnering in the conference software is now linked on the with Inteleos drug records. We have made your research even easier by giving you all the info you need to prepare for partnering meetings.

TA Partnerships is more personalized and has the highest concentration of the right decision-makers, making it the most exclusive, personalized global partnering meeting out there.


For every 2 paid attendees, get the 3rd FREE!

For more information, please contact:
Pat Cardone at 203.840.6272 or email P.Cardone@Elsevier.com.

Brochure in Adobe PDF format. Coming Soon!

STAY CONNECTED
Join our Therapeutic Area Partnerships event on

Conference Snapshot

• A uniquely focused meeting among R&D, financing and business development leadership to improve the partnering process and encourage innovative thinking about productivity and dealmaking
• Gain insights to pick targets and compounds likely to succeed)
• Identify the right drugs and the right partners
• Therapeutic Area challenges and opportunities: Who will win, Who won’t, and Where are you in the mix
• Expert advisers and strategic decision-makers help make sure your company is one of the winners
• Independent experts select the ten most promising clinical programs available for partnering in oncology, neuroscience, cardiovascular and metabolic, autoimmune and inflammatory, infectious disease and hot space therapeutic area tracks
• Discover ways to finance Innovation and innovate dealmaking
• What new ways of thinking can break down barriers to new medicines and how can partnering and financing drive the process?

Who Should Attend?

Biotech CEOs, Strategic Alliances, Business and Corporate Development, Commercial Analytics & Decision Support, Licensing, Global Discovery Alliance, Financial Planning & Analysis, Alliance Management, Venture Capital, Bankers & Service Providers

Here's What Past Attendees Say:

"The efforts to identify the ‘Top 10 Products Available for Partnering’ were well done. The product opportunities were well profiled and the conference provided an excellent forum for serious partnering activity."

"Top 10 idea is superb. They might not be the only products to fit the criteria, but hard to find any not deserving."

"Few conferences offer such focus and insight for partnering."

"A good opportunity to bring together a host of Business Development individuals through a common interest."

"Good overview of opportunities in the Therapeutic Areas. Good partnering opportunities present at the meeting."

"So efficient to focus on the specific TAs. Made my partnering meetings much more focused."

Conference Snapshot

Who Should Attend?

Here's What Past Attendees Say:

Sponsors